Home / Fact sheets / Population fact sheet
The World Bank (2016)
World Health Organization (2015)
UNDP Human Development Report (2015)
The World Bank (2016)
GLOBOCAN (2018)
Country fact sheet: France
| - Total population: | 66 892 205 |
| - Female population: | 34 013 206 |
| - Male population: | 32 878 999 |
Health Expenditure
| - Total per capita (US$): | 4 026.1 |
| - Out-of-pocket (% of total expenditure on health): | 6.8 |
Human Development Index
| - HDI: | 0.897 |
| - Category: | Very high |
Geography
 |
Life Expectancy at Birth
| - Total population (years): | 82.3 |
| - Female population (years): | 85.5 |
| - Male population (years): | 79.2 |
Cancer Burden
| - Overall cancer incidence (rate per 100 000 persons per year): | 344.1 |
| - Overall cancer mortality (rate per 100 000 persons per year): | 109.8 |
| - Most common cancer site by incidence for females (rate per 100 000 persons per year): | Breast (99.1) |
| - Most common cancer site by mortality for females (rate per 100 000 persons per year): | Breast (15.4) |
| - Most common cancer site by incidence for males (rate per 100 000 persons per year): | Prostate (99.0) |
| - Most common cancer site by mortality for males (rate per 100 000 persons per year): | Lung (38.9) |
| - GLOBOCAN 2018 population fact sheet |
Screening programmes
    |
BREAST CANCER SCREENING PROGRAMME
| Last updated year for qualitative data: | 2016 |
| Source of data: | Report (EU Report 2017) |
| Last updated year for quantitative data: | 2012 |
| Source of data: | Report (EU Report 2017) |
Screening protocol | |
| Year published/updated: |  |
| Screening test used: | 1 |
| Target age (min-max) and screening interval [months] for each test: | Mammography + CBE/US (50-74 years / [24 months] ) |
Programme status and organization | |
| Dedicated person/team to coordinate the programme: | |
| Budget line for screening programme: | |
| Documented cancer screening policy: | |
| Nature of documentation of the policy: | |
| Program introduction was preceded by a pilot: | |
| Year program was initiated: | 2004 |
| Screening tests provided free of charge: | |
| Diagnostic tests provided free of charge: |  |
| Treatment services provided free of charge: | |
Information system/Data collection | |
| Data type collected by the programme: | Individual and aggregate |
| The information system collects data outside the program (opportunistic screening/private sector): | |
| Cancer screening registries covering the entire country/region: | |
| Cancer screening data is linked with Population-based cancer registry: | |
Invitation to screening and further assessment | |
| Method of identification of eligible individuals: | From population data |
| Source of population data: | |
| Annual target for screening coverage: | |
| Invitations to eligible population: | |
| Method of invitation: | |
| Screen positive individuals actively invited for further assessment: | |
| Individuals with a precancer or cancer diagnosis actively contacted: | |
| Program collects data on the treatment of precancer/cancers: | |
Programme monitoring and quality assurance (QA) | |
| Documented standard operating procedure/policy for QA: | |
| Responsible person/team for QA: | |
| Documented performance indicators and their reference standards to assess the programme: | |
| Evaluation reports are prepared and published: | |
Cancer Screening programme status | |
| Nature of cancer screening programme: | Population-based and non population-based |
| Current status of implementation (applicable only for population-based programmes): | |
| Cancer screening programme population based for selected populations: | |
Performance indicators | |
| Target age and regional limitation if applicable: | 50-69 years |
| Invitation coverage (%): | 102.7 |
| Examination coverage (%): | 52.3 |
| Participation rate (%): | 51 |
| Completeness of data related to screening results (%): | 99.4 |
| Completeness of data related to further assessment results (%): | 94.4 |
| Further assessment rate (%): | 9.4 |
| Further assessment participation rate (%): | 96.0 |
| Detection rate of CIS and invasive (x 1000): | 6.74 |
| Detection rate of invasive cancer (x 1000): | 1.02 |
| Positive predictive value of further assessment to detect CIS and invasive (%): | 7.5 |
| Proportion of total carcinomas which are CIS (%): | 15.1 |
| Benign surgical biopsy rate (x 1000): | 1.26 |
| More quantitative data (2012) | |
CERVICAL CANCER SCREENING PROGRAMME
| Last updated year for qualitative data: | 2016 |
| Source of data: | Report (EU Report 2017) |
| Last updated year for quantitative data: | 2010-2012 |
| Source of data: | Report (EU Report 2017) |
Screening protocol | |
| Year published/updated: | |
| Screening test used: | 1 |
| Target age (min-max) and screening interval [months] for each test: | Cytology (25-64 years / [36 months] ) |
| Triaging test used: | None |
| "screen and treat" included in the protocol: | |
Programme status and organization | |
| Dedicated person/team to coordinate the programme: | |
| Budget line for screening programme: | |
| Documented cancer screening policy: | |
| Nature of documentation of the policy: | |
| Program introduction was preceded by a pilot: | |
| Year program was initiated: | 1991 |
| Screening tests provided free of charge: | |
| Diagnostic tests provided free of charge: | |
| Treatment services provided free of charge: | |
Information system/Data collection | |
| Data type collected by the programme: | Individual and aggregate |
| The information system collects data outside the program (opportunistic screening/private sector): | |
| Cancer screening registries covering the entire country/region: | |
| Cancer screening data is linked with population-based cancer registry: | |
Invitation to screening and further assessment | |
| Method of identification of eligible individuals: | From population data |
| Source of population data: | Population register |
| Annual target for screening coverage: | |
| Invitations to eligible population: | Excluding those covered by opportunistic screening |
| Screening kit included with the invitation: | |
| Method of invitation: | letter |
| Screen positive individuals actively invited for further assessment: | |
| Individuals with a precancer or cancer diagnosis actively contacted: | |
| Program collects data on the treatment of precancer/cancers: | |
Programme monitoring and quality assurance (QA) | |
| Documented standard operating procedure/policy for QA: | |
| Responsible person/team for QA: | |
| Documented performance indicators and their reference standards to assess the programme: | |
| Evaluation reports are prepared and published: | |
Cancer Screening programme status | |
| Nature of cancer screening programme: | Population-based and non population-based |
| Current status of implementation: | Roll-out on going |
| Cancer screening programme population based for selected populations/regions: | |
Performance indicators | |
| Target age and regional limitation if applicable: | 30-59 years (13 regions) |
| Invitation coverage (%): | 53.6 |
| Examination coverage (invitation cohort) (%): | 11.7 |
| Examination coverage (tests in the index-year) (%): | 63.1 |
| Participation rate (%): | 21.9 |
| Completeness of data related to screening test results (%): | |
| Completeness of data related to further assessment results (%): | |
| Colposcopy referral rate (%): | |
| Colposcopy participation rate (%): | |
| Detection rate of CIN2+ (x 1000): | |
| Detection rate of CIN3+ (x 1000): | |
| Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000): | |
| Positive Predictive Value of CIN3+ (x 1000): | |
| More quantitative data (13 regions: 2010-2012) | |
COLORECTAL CANCER SCREENING PROGRAMME
| Last updated year for qualitative data: | 2012 |
| Source of data: | Report (EU Report 2017) |
| Last updated year for quantitative data: | 2012 |
| Source of data: | No source |
Screening protocol | |
| Year published/updated: | |
| Screening test used: | 2 |
| Target age (min-max) and screening interval [months] for each test: | FIT: (50-74 years / [24 months] ) gFOBT: (50-74 years / [24 months] ) |
Programme status and organization | |
| Dedicated person/team to coordinate the programme: | |
| Budget line for screening programme: | |
| Documented cancer screening policy: | |
| Nature of documentation of the policy: | Official recommendation |
| Program introduction was preceded by a pilot: | |
| Year program was initiated: | 2002 |
| Screening tests provided free of charge: | |
| Diagnostic tests provided free of charge: | |
| Treatment services provided free of charge: | |
Information system/Data collection | |
| Data type collected by the programme: | Individual and aggregate |
| The information system collects data outside the program (opportunistic screening/private sector): | |
| Cancer screening registries covering the entire country/region: | |
| Cancer screening data is linked with population-based cancer registry: | |
Invitation to screening and further assessment | |
| Method of identification of eligible individuals: | From population data |
| Source of population data: | List from insurance company |
| Annual target for screening coverage: | |
| Invitations to eligible population: | For the entire target population |
| Method of invitation: | letter |
| Screen positive individuals actively invited for further assessment: | |
| Individuals with a precancer or cancer diagnosis actively contacted: | |
| Program collects data on the treatment of precancer/cancers: | |
Programme monitoring and quality assurance (QA) | |
| Documented standard operating procedure/policy for QA: | |
| Responsible person/team for QA: | |
| Documented performance indicators and their reference standards to assess the programme: | |
| Evaluation reports are prepared and published: | |
Cancer Screening programme status | |
| Nature of cancer screening programme: | Population-based and non population-based |
| Current status of implementation (applicable only for population-based programmes): | Roll-out completed |
| Cancer screening programme population based for selected populations: | |
Performance indicators | |
| FIT | gFOBT | sigmoidoscopy | Colonoscopy | |
| Target age and regional limitation if applicable: | 50-74 (Calvados) | 50-74 | ||
| Invitation coverage (%): | 88.2 | 97.0 | ||
| Examination coverage (%): | 20.1 | 23.7 | ||
| Participation rate (%): | 22.8 | 24.4 | ||
| Completeness of data related to screening results (%): | 99.2 | 97.9 | ||
| Completeness of data related to information about attendance to colonoscopy assessment (%): | 100.1 | 100.0 | ||
| Completeness of data related to histology result (%): | 99.9 | 99.0 | ||
| Screen positivity (indication for follow-up colonoscopy) rate (%) : | 3.3 | 2.2 | ||
| Follow-up colonoscopy participation rate (%): | 87.9 | 84.0 | ||
| Completion rate follow-up colonoscopy (%): | 93.8 | 93.8 | ||
| Detection rate of adenomas (x 1000): | 10.7 | 6.1 | ||
| Detection rate of advanced adenomas (x 1000): | 6.0 | 3.6 | ||
| Detection rate of colorectal cancers (x 1000): | 1.8 | 0.6 | ||
| Positive Predictive Value of further assessment to detect adenomas (%): | 37.5 | 33.6 | ||
| Positive Predictive Value of further assessment to detect advanced adenomas (%): | 21.2 | 19.8 | ||
| Positive Predictive Value of further assessment to detect colorectal cancers (%): | 6.3 | 3.5 | ||
| More quantitative data for gFOBT (Male - 2012) | ||||
| More quantitative data for gFOBT (Women - 2012) | ||||
| More quantitative data for FIT (Male - Calvados: 2012) | ||||
| More quantitative data for FIT (Women - Calvados: 2012) |